Safety, reactogenicity, and immunogenicity of a 12-valent pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccine in healthy toddlers: results from a phase I, randomized trial

• Egile Nagusiak: Michael Horn (Egilea), Ulrich Behre (Egilea), Magali Traskine (Egilea), Kurt Dobbelaere (Egilea), Dorota Borys (Egilea)
• Formatua: Liburua
• Argitaratua: Taylor & Francis Group, 2021-05-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

As a stepping stone toward evaluation in infants, the safety and immunogenicity of an investigational 12-valent pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccine (12vPHiD-CV) was assessed in toddlers. 12vPHiD-CV contains CRM197-conjugated capsular polysaccharides of seroty...